Roles: no actor should disappear behind software
A design should distinguish the participant, investigator, legal sponsor, licensed clinician, institutional or independent IRB, laboratory, data custodian, statistical reviewer, and public reporting entity. Some individuals may have several roles; each role should still be documented. Decentralization changes where tasks occur, not the fact that someone is answerable for them. F02F05F18
For interventional studies, the sponsor retains applicable obligations for monitoring, record systems and safety reports, including after permissible delegation. Written agreements should identify exactly which duties transfer and which remain independently required. A local clinician needs protocol training, authorized scope, an adverse-event escalation line and communication back to the sponsor. F04F05F06
A national support network could provide neutral protocol and analytics services while maintaining conflict-of-interest boundaries from product marketers. Where regulatory interpretation is uncertain, the applicant should request a written classification decision and record it as part of project governance.
The participant experience as a research-quality variable
Enrollment should present a straightforward explanation of the research question, expected activity, alternatives, known and unknown risks, withdrawal and privacy terms. The participant should have a durable copy of consent choices and an accessible human contact. Remote consent may improve convenience, but digital literacy and accessibility limitations can reduce comprehension if the process is poorly designed. F07F08P02P05
Study participation may involve telehealth, local sample collection or home monitoring. Each event requires time stamps, staff identity, protocol version and quality control appropriate to the measure. An event can be digitally signed or recorded without copying private health facts onto a public chain. If an event fails or a participant reports a problem, the system must route that information to a responsible human.
The commons should also report back understandable outcomes, including null findings and methodological limitations. Participants should not merely become free data sources for a commercial model. The 2025 participant-partnership literature emphasizes considering value returned to participants and intentional engagement throughout decentralized studies. P02
Evidence pipeline and measurement standards
Data collection needs a codebook, allowed value ranges, time-zone and unit normalization, device provenance, versioned instrument definitions, correction history and missingness rules. Common endpoints should use validated scales when possible, and custom measurements should be labeled exploratory. Laboratory values should be recorded with method and reference context rather than assumed to be directly comparable.
A statistical analysis plan should be written before outcome inspection to limit flexible analysis. The plan should identify primary and secondary endpoints, confounders, anticipated sample sizes or precision targets, how missing data are treated, whether repeated measurements are autocorrelated, how multiplicity is controlled, and which uncertainty estimates will be reported. P06P07P08
A shared register of protocols could include prospective version history, deviations, adverse-event summaries and public result status. It should allow legitimate confidential details to remain protected while preventing invisible deletion of unfavorable results. The goal is interpretable aggregate evidence, not an enormous unreviewed health-data lake.
Federated computation and participant data permissions
A feasible architecture stores identifying information under separately governed custody, places encrypted observations under study-specific access restrictions, and limits linkage keys to authorized processes. It may analyze local datasets through federated methods, but federation alone does not guarantee anonymity, data security or protection from membership inference. F14F15
Participation tokens should be access-control receipts, not claims of immutable health-data ownership. The record can identify which project, dataset, recipient, purpose, expiry and withdrawal status an access grant covers. Off-chain encrypted stores, revocable credentials, retention rules and logs can implement choices; legal obligations must still govern recipients who export copies.
AI use should be split into distinct classes: summarization for a participant, statistical assistance for an approved study, model inference on restricted data, generalized model training, and commercial secondary use. Opt-in and withdrawal can apply separately to future activity, while legitimate retention and already completed derived outputs may require explicit contractual or statutory treatment.
Scientific and legal acceptance criteria
Before any project accepts participants, the record should contain a documented regulatory determination, sponsor and investigator responsibilities, review decisions if applicable, protocol, consent version, risk assessment, incident handling plan, supply documentation where relevant, and privacy/data-use terms. The requirements differ by type of activity; publishing an API endpoint or creating a database does not satisfy them.
After launch, evaluation should include protocol adherence, sample quality, data completeness, safety event response time, scientifically interpretable outcome reporting and real complaints resolved. An audit must be able to answer who changed a consent record, why a measurement was excluded and whether a participant's future data-use restrictions were honored.
An initial demonstration should use non-interventional and lawfully supervised workflows. A separate investigational intervention program would require its own regulatory authorization and product-specific quality and safety systems. These stages keep the civic campaign, research software and actual clinical investigations from being conflated.